Nykode Therapeutics AS

Norway’s Nykode Therapeutics is coming to terms with Roche’s surprise decision earlier this month to end the firms' cancer vaccine partnership, with significant job losses an inevitable consequence. T

The mood around the BIO-Europe conference in Munich in November was positive as people in the biotech world, or at least 5,500 of them, gathered to talk shop at over 30,000 partnering meetings. Howeve

Having just completed a private placement of $45m, adding to its healthy cash reserves, Norwegian biotech Nykode Therapeutics AS is carrying on with plans to list stateside while advancing its cervi

The ecosystem between biotech and pharma has never been richer and "it's so interesting to see that symbiosis working so well." So said James Sabry, global head of pharma partnering at Roche Holding